Loading...
•
Sep 30, 2022
ACADIA Q3 2022 Earnings Report
Reported continued growth in demand for NUPLAZID and advanced trofinetide NDA filing.
Key Takeaways
Acadia Pharmaceuticals reported Q3 2022 financial results with NUPLAZID net sales of $130.7 million. The company's trofinetide NDA for Rett syndrome was accepted for filing by the FDA.
NUPLAZID net sales were $130.7 million in Q3 2022.
Sequential demand growth of 2% for NUPLAZID was achieved.
Trofinetide NDA for Rett syndrome was accepted for filing by the FDA with a PDUFA action date of March 12, 2023.
ADVANCE-2, a Phase 3 study evaluating pimavanserin, expects enrollment to complete around mid-year 2023.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.com Forward Guidance
Acadia updated its 2022 financial guidance.
Positive Outlook
- NUPLAZID net sales guidance is updated to $510 to $520 million.
- GAAP R&D guidance is updated to $345 to $355 million, which includes approximately $25 million of stock-based compensation expense.
- GAAP SG&A guidance is updated to $365 to $375 million, which includes approximately $45 million of stock-based compensation expense.